News

May 20, 2022

Matthew Vander Heiden, MD, PhD

Matthew Vander Heiden, M.D., Ph.D., is an Associate Professor in the Department of Biology at the Massachusetts Institute of Technology, and Associate Director of the Koch Institute for Integrative Cancer Research.  He is also an HHMI Faculty Scholar, an Institute Member of the Broad Institute of Harvard and MIT, and an Instructor of Medicine at…

May 20, 2022

Eytan Stein, MD

Eytan M. Stein, MD is an Associate Attending Physician, Clinical Investigator and Director of the Program for Drug Development in Leukemia on the Leukemia Service at Memorial Sloan Kettering Cancer Center. He conducts novel, phase I clinical trials of compounds that target the genetic and epigenetic basis of myeloid malignancies. Dr. Stein led the clinical…

May 20, 2022

Ross Levine, MD

Ross Levine, M.D., is a Member of the Human Oncology and Pathogenesis Program and an Attending Physician on the Leukemia Service, Department of Medicine at Memorial Sloan Kettering (MSK).  He is the Laurence Joseph Dineen Chair in Leukemia Research, a Professor of Medicine at Weill Cornell Medical College, and the Director of the MSK Center…

May 20, 2022

Kate Yen, PhD

Kate Yen, PhD, is the Founder and CEO of Auron Therapeutics. Prior to founding Auron, she was a Director at Agios Pharmaceuticals, where she led the IDH translational research team that supported the preclinical and clinical development and approval of two IDH mutant inhibitors, IDHIFA and TIPSOVO. She led the proof of concept studies that…